Raphael Pharmaceutical Inc. (OTC: RAPH)

Raphael Pharmaceutical Inc. is a pharmaceutical drug research and development company focused on the discovery and clinical development of life improving drug therapies based on cannabinoids, including cannabidiol, or CBD, oil. The company concentrates its efforts on treating rheumatoid arthritis, asthma, and inflammation related to conditions such as COVID 19. To date it has completed a proof of concept clinical study in the United States for its lead cannabinoid based formula targeting rheumatoid arthritis and has launched a branded dietary supplement called RaphaWell for rheumatoid arthritis support. In parallel it is advancing preclinical programs for asthma and is exploring potential applications in other autoimmune diseases such as psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus with neutrophil involvement, and gout. The firm conducts its research primarily through a sponsored agreement with Rambam Health Care Campus in Israel and utilizes contract research organizations for clinical testing in the United States.

The company does not yet generate revenue from product sales; instead, it expects to earn income through licensing agreements, milestone payments, and royalties from future sales of its drug candidates. Under its agreement with Way of Life Cannabis Ltd., Raphael Pharmaceutical is entitled to a royalty equal to 15 percent of net income derived from sales of its cannabinoid based products. Additionally, the firm anticipates receiving payments from partners that manufacture and distribute its approved therapies under good manufacturing practice standards. Revenue may also arise from the out licensing of its patent pending technology platform to third parties seeking to develop cannabinoid based treatments.

Raphael Pharmaceutical positions itself as an emerging developer of cannabinoid based therapeutics in a competitive landscape that includes large pharmaceutical firms, specialty biotech companies, and academic research groups. Its competitive advantages stem from proprietary formulations, a patent pending technology platform, and a long standing research collaboration with Rambam Health Care Campus that provides preclinical validation and intellectual property sharing. The company benefits from early clinical data showing improvement in disease activity scores and patient reported outcomes for its rheumatoid arthritis formula. Moreover, its focus on non psychoactive cannabidiol extracts with less than 0.3 percent tetrahydrocannabinol aligns with regulatory trends favoring hemp derived ingredients. While it faces competition from established disease modifying anti rheumatic drugs and biologic agents, the firm believes its mechanism of action via immune cell modulation offers a differentiated approach.

The company’s current collaborators and anticipated customers include research institutions such as Rambam Health Care Campus and its Medical Cannabis Research and Innovation Center, contract research organizations like Citruslabs, and commercial partners such as Way of Life Cannabis Ltd. These relationships support preclinical studies, clinical trials, and the supply of cannabinoid oil for research and development. Ultimately, the therapies are intended for patients suffering from rheumatoid arthritis, asthma, and related inflammatory conditions, with the goal of providing treatment options through licensed manufacturers and distributors. Raphael Pharmaceutical also engages with regulatory bodies such as the U. S. Food and Drug Administration and the Israeli Ministry of Health to advance its product candidates toward approval.